Skip to main content

Kidney Transplant; Complications

Nephrology
5
Pipeline Programs
9
Companies
13
Clinical Trials
2 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
1
0
2
2
Early DiscoveryClinical DevelopmentMarket

Nephrology is a $36.6B mature market dominated by cardiometabolic crossover drugs with limited pure renal innovation.

$36.6B marketMature→ Stable30 products15 companies

Key Trends

  • GLP-1 agonists and SGLT2 inhibitors dominate (69% of spending) due to dual cardio-renal benefits
  • Patent cliffs approaching 2026-2030 create generic conversion risk for blockbuster franchises
  • Pipeline activity remains robust (2,785 trials) but concentrated in early-phase basic research

Career Verdict

Nephrology offers stable employment in commercial and medical affairs roles, but limited growth upside due to mature blockbuster dependency and declining pure renal research focus.

AI-generated market analysis based on FDA, CMS, ClinicalTrials.gov, and hiring data

Market Leaders

#1OZEMPICStable
$9.2B
Novo Nordisk·Peak12.4yr
#2JARDIANCEStable
$8.8B
Boehringer Ingelheim·Peak8.6yr
#3TRULICITYStable
$7.4B
Eli Lilly and Company·Peak
#4FARXIGAStable
$4.3B
AstraZeneca·Peak15.4yr

Drug Class Breakdown

Glucagon-like Peptide-1 (GLP-1) Agonists
$16.6B(45%)

cardiometabolic dominance

Sodium-Glucose Transporter 2 Inhibitors
$8.8B(24%)

cardioprotective expansion

SGLT2 Inhibitors (dapagliflozin class)
$4.3B(12%)

heart failure crossover

Adrenergic Beta3-Agonists
$3.0B(8%)

overactive bladder niche

Dipeptidyl Peptidase 4 Inhibitors
$1.3B(4%)

declining relevance

Career Outlook

Stable

Nephrology careers are stable but not expanding; the field is supported by blockbuster drugs (GLP-1s, SGLT2i) that face patent cliffs between 2026–2041, creating near-term employment security but long-term uncertainty. Commercial and medical affairs roles dominate hiring, while R&D investment is limited to niche mechanisms (complement inhibition, gene therapy). Career progression depends on specialization in medtech, diagnostics, or orphan nephrology rather than traditional pharma blockbuster development.

Breaking In

Target medtech platforms (Outset, Fresenius) or biotech innovators (Vertex, Calyxo) over traditional pharma; nephrology offers job stability and clinical depth but limited growth trajectory in pure pharmaceutical roles.

For Experienced Professionals

Leverage cardiometabolic expertise to span diabetes, CKD, and HF franchises; position for transition to orphan nephrology (ADPKD, FSGS, IgA) where innovation and valuation multiples are highest.

In-Demand Skills

Renal endpoints and biomarkers (eGFR, albuminuria)Cardio-renal crossover knowledge (diabetes + CKD + HF)Medtech systems expertise (dialysis, transplantation platforms)Medical affairs and key opinion leader management

Best For

Medical Science Liaison (renal specialists)Commercial Manager (established nephro franchise)Clinical Development Manager (rare kidney disease)Real-world evidence analyst (CKD outcomes)

Hiring Landscape

$108K–$330K

Nephrology hiring is concentrated in commercial roles (58 positions, $108K avg) and medical affairs (12 positions, $330K avg), reflecting mature market dynamics. Top hiring companies are innovative platforms (Vertex: 41 jobs) and medtech (Outset: 21 jobs), not traditional pharma. Salary compression in commercial roles suggests commoditization.

124
Open Roles
5
Companies Hiring
4
Departments

Top Hiring Companies

Vertex Pharmaceuticals
41Growing
Outset Medical
21Growing
Calyxo
20Growing
Biogen
8Stable
AstraZeneca
5Stable

By Department

Commercial(47%)
$108K
Medical Affairs(10%)
$330K
Clinical Excellence(6%)
$140K
Quality Assurance(4%)
$201K

Hiring favors medtech and biotech platforms over traditional pharma; medical affairs offers premium compensation but limited volume; commercial roles are abundant but underpaid relative to other therapeutic areas.

Competitive Landscape

9 companies ranked by most advanced pipeline stage

Colorado Therapeutics
Colorado TherapeuticsCO - Louisville
3 programs
2
Dapagliflozin 10mg TabPhase 41 trial
SugammadexPhase 41 trial
Sodium BicarbonateN/A1 trial
Active Trials
NCT03428464Completed20Est. Mar 2020
NCT06140537Recruiting80Est. Dec 2028
NCT03923556Completed84Est. Oct 2023
Sharp Therapeutics
Sharp TherapeuticsPA - Pittsburgh
1 program
1
Letermovir 480 mg once dailyPhase 31 trial
Active Trials
NCT06001320Active Not Recruiting30Est. Sep 2026
MSD
MSDIreland - Ballydine
1 program
1
Letermovir 480 mg once dailyPhase 3
Medice
MediceGermany - Iserlohn
1 program
1
Low dose sodium bicarbonatePhase 21 trial
Active Trials
NCT03301558Withdrawn0Est. Dec 2025
Veloxis Pharmaceuticals
4 programs
Tacrolimus, Extended Release,PHASE_11 trial
EnvarsusPHASE_41 trial
Extended Release Tacrolimus TabletsPHASE_41 trial
Once daily immunosuppression regimenPHASE_41 trial
Active Trials
NCT03410654Completed28Est. Jul 2024
NCT03461445Completed64Est. Jul 2023
NCT03841097Active Not Recruiting60Est. May 2026
+1 more trials
T-Therapeutics
T-TherapeuticsUK - Cambridge
1 program
Bioimpedance SpectroscopyN/A1 trial
Active Trials
NCT04451356UnknownEst. Dec 2022
Dexcom
DexcomCA - San Diego
1 program
Dexcom G6N/A1 trial
Active Trials
NCT04783441Recruiting80Est. Dec 2026
Nielsen BioSciences
Nielsen BioSciencesCA - San Diego
1 program
Herpes Virus Infections in Kidney Transplant PatientsN/A1 trial
Active Trials
NCT05604911Active Not Recruiting280Est. Feb 2026
Genomics
GenomicsUK - Oxford
1 program
TruGraf testN/A1 trial
Active Trials
NCT04280276Terminated13Est. Mar 2022

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
Colorado TherapeuticsDapagliflozin 10mg Tab
Colorado TherapeuticsSugammadex
Veloxis PharmaceuticalsExtended Release Tacrolimus Tablets
Veloxis PharmaceuticalsOnce daily immunosuppression regimen
Veloxis PharmaceuticalsEnvarsus
Sharp TherapeuticsLetermovir 480 mg once daily
MediceLow dose sodium bicarbonate
Veloxis PharmaceuticalsTacrolimus, Extended Release,
Nielsen BioSciencesHerpes Virus Infections in Kidney Transplant Patients
DexcomDexcom G6
GenomicsTruGraf test
T-TherapeuticsBioimpedance Spectroscopy
Colorado TherapeuticsSodium Bicarbonate

Clinical Trials (13)

Total enrollment: 790 patients across 13 trials

NCT06140537Colorado TherapeuticsDapagliflozin 10mg Tab

Efficacy and Mechanisms of Dapagliflozin in Promoting Kidney Function and Cardiovascular Health in Kidney Transplant Recipients

Start: Feb 2024Est. completion: Dec 202880 patients
Phase 4Recruiting
NCT03923556Colorado TherapeuticsSugammadex

Sugammadex Versus Neostigmine for Reversal of Neuromuscular Blockade at the End of Kidney Transplantation Surgery

Start: Feb 2021Est. completion: Oct 202384 patients
Phase 4Completed
NCT03841097Veloxis PharmaceuticalsExtended Release Tacrolimus Tablets

Pulse Wave Velocity, Tacrolimus Time in Therapeutic Range and CV in African American Kidney Transplants

Start: Nov 2019Est. completion: May 202660 patients
Phase 4Active Not Recruiting
NCT03555448Veloxis PharmaceuticalsOnce daily immunosuppression regimen

Once Daily Immunosuppression Regimen

Start: Jun 2018Est. completion: Nov 202351 patients
Phase 4Terminated
NCT03461445Veloxis PharmaceuticalsEnvarsus

Effect of Tacrolimus Formulation on Neurological Side Effects in Older Kidney Transplant Recipients

Start: Apr 2018Est. completion: Jul 202364 patients
Phase 4Completed
NCT06001320Sharp TherapeuticsLetermovir 480 mg once daily

De-novo Initiation of Letermovir vs Valganciclovir for Cytomegalovirus Prophylaxis in AA Kidney Transplant Recipients

Start: Sep 2023Est. completion: Sep 202630 patients
Phase 3Active Not Recruiting
NCT03301558MediceLow dose sodium bicarbonate

The Effect of Sodium Bicarbonate (Nephrotrans®) on Calcification Propensity of Serum in Kidney Transplant Recipients

Start: Dec 2025Est. completion: Dec 20250
Phase 2Withdrawn
NCT03410654Veloxis PharmaceuticalsTacrolimus, Extended Release,

Assessment of Cognitive Function Before and After Conversion From Immediate Release Tacrolimus to Envarsus XR.

Start: Oct 2018Est. completion: Jul 202428 patients
Phase 1Completed
NCT05604911Nielsen BioSciencesHerpes Virus Infections in Kidney Transplant Patients

Herpes Virus Infections in Kidney Transplant Patients

Start: Jan 2023Est. completion: Feb 2026280 patients
N/AActive Not Recruiting
NCT04783441DexcomDexcom G6

Use of CGM in Kidney Transplant Recipients

Start: Jun 2021Est. completion: Dec 202680 patients
N/ARecruiting
NCT04280276GenomicsTruGraf test

TruGraf Utilization in High IPV Levels

Start: Mar 2020Est. completion: Mar 202213 patients
N/ATerminated
NCT04451356T-TherapeuticsBioimpedance Spectroscopy

Romanian Kidney Transplant Cardiovascular Risk Registry

Start: Feb 2020Est. completion: Dec 2022
N/AUnknown
NCT03428464Colorado TherapeuticsSodium Bicarbonate

Bicarbonate Administration in Kidney Transplant Recipients

Start: Dec 2018Est. completion: Mar 202020 patients
N/ACompleted

Related Jobs in Nephrology

Junior CAD Designer (Solidworks)

Outset MedicalOutset Medical
Tijuana, Mexico
Yesterday

Therapy Specialist, Peritoneal Dialysis, Southern Poland

Baxter InternationalBaxter International
Warsaw, Masovian
Yesterday

Field Service Engineer II (Andover, MA)

Outset MedicalOutset Medical
Andover, MA
Yesterday
$71K - $83K/yr

Sr. R&D Engineer, Instruments - Pleasanton, CA

CalyxoCalyxo
Pleasanton, CA
Yesterday
$140K - $160K/yr

Project Manager, On-Market Products - Pleasanton, CA

CalyxoCalyxo
Pleasanton, CA
2d ago
$130K - $140K/yr

Staff Systems Engineer - Pleasanton, CA

CalyxoCalyxo
Pleasanton, CA
2d ago
$195K - $205K/yr

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

2 late-stage (Phase 3) programs, potential near-term approvals
2 actively recruiting trials targeting 790 patients
9 companies competing in this space

Related Indications

Chronic Kidney Disease(220)End Stage Renal Disease(203)Renal Impairment(142)Kidney Transplantation(136)Chronic Kidney Diseases(71)Acute Kidney Injury(66)Renal Insufficiency(66)Kidney Diseases(46)Renal Transplantation(45)Kidney Transplant(41)

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.